Yan Baglo
About
Ph.D. in Molecular Medicine, 2014.
Department of Cancer Research and Molecular Medicine, NTNU, Norway.
Postdoc 2015-2018
Wellman Center for Photomedicine at Harvard Medical School/Massachusetts General Hospital, Boston, USA
Postdoc 2018-2020
Fischell Department of Bioengineering at the University of Maryland, College Park, USA
Competencies
Publications
Systematic Evaluation of Light-Activatable Biohybrids for Anti-Glioma Photodynamic Therapy
We prepared and characterized three well-defined photosensitizing biomolecules based on a clinically used photosensitizer, benzoporphyrin derivative (BPD).
Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy
We demonstrate that light-based photodynamic priming (PDP) coupled with vitamin D3 receptor (VDR) activation within fibroblasts increases intratumoral nanoliposomal irinotecan accumulation and suppresses protumorigenic CXCL12/CXCR7 crosstalk.
Evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy
This study used the FDA-approved benzoporphyrin derivative (BPD) photosensitizer or its lipidated formulation ((16:0)LysoPC-BPD) to kill OVCAR-8 cells and reduce the likelihood that olaparib-resistant cells would have selective advantage.
Harnessing the Potential Synergistic Interplay Between Photosensitizer Dark Toxicity and Chemotherapy
Our study provides insights into the molecular alterations in two glioma lines caused by each monotherapy and the combinations, in order to inform the design of effective treatments.
Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells
We verify that P-gp, like ABCG2, plays a role in BPD transport and BPD-PDT resistance. Furthermore, we introduce porphyrin-lipid nanovesicles to escape P-gp and ABCG2-mediated efflux of BPD for improved PDT outcomes in two breast cancer cell lines.
Photoinactivation of Neisseria gonorrhoeae: A Paradigm-Changing Approach for Combating Antibiotic-Resistant Gonococcal Infection
Our findings indicated that antimicrobial blue light (aBL; wavelength, 405 nm) preferentially inactivated N. gonorrhoeae, including antibiotic-resistant strains, over human vaginal epithelial cells in vitro.
Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting
We developed a novel photoimmunoconjugate-nanoliposome comprising of three clinically used agents: anti-epidermal growth factor receptor monoclonal antibody cetuximab, benzoporphyrin derivative photosensitizer, and irinotecan chemotherapy.
Modulation of redox metabolism negates cancer-associated fibroblasts-induced treatment resistance in a heterotypic 3D culture platform of pancreatic cancer
In this study, a modular 3D culture model that comprised PDAC cells and patient-derived cancer-associated fibroblasts (CAFs) was developed to assess the effects of PDAC-CAF interactions on treatment efficacies.
Antimicrobial Blue Light Inactivation of Neisseria gonorrhoeae: Roles of Wavelength, Endogenous Photosensitizer, Oxygen, and Reactive Oxygen Species
The aim of this study was to investigate the efficacy, safety, and mechanism of action of antimicrobial blue light (aBL) for the inactivation of Neisseria gonorrhoeae, the etiological agent of gonorrhea.
Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery
In this study, we present preclinical evidence that a subtumoricidal photodynamic priming (PDP) strategy can relieve drug delivery barriers in the tumor microenvironment to safely widen the therapeutic window of a nanoformulated cytotoxic drug.
Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase Inhibition for Peritoneal Carcinomatosis
We show that the antibiotic minocycline, by its ability to minimize DNA repair via reduced expression of tyrosyl-DNA phosphodiesterase-1 (Tdp1), removes a key process attenuating the efficacy of irinotecan.